Bristol-Myers Squibb (BMY) news

Confirm that we have ended our partnership with Cellares. - Bristol Myers spokesperson

Bristol Myers Squibb has confirmed that it has ended its partnership with Cellares, according to a statement from a Bristol Myers spokesperson. The partnership had included a $380 million capacity reservation and supply agreement for the manufacture of CAR T cell therapies using Cellares’…

Chai Discovery reports pact with Bristol Myers Squibb

U.S. FDA grants accelerated approval to Bristol Myers Squibb's first CELMoD therapy ZENBEXUS% in combination with

The U.S. Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s New Drug Application (NDA) for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) FDA accepted Bristol Myers…

FDA grants accelerated approval to Bristol-Myers Zenbexus combo

Cytokinetics - files complaint against Bristol-Myers Squibb and Myokardia - SEC filing

Cytokinetics Inc. has filed a complaint with the U.S. Securities and Exchange Commission (SEC) against Bristol-Myers Squibb Company and Myokardia Inc., alleging violations related to financial disclosures and business practices. The complaint, detailed in a recent SEC filing, centers on alleged…